RedHill Biopharma (RDHL) Gains from Sales and Divestitures: 2011-2025
Historic Gains from Sales and Divestitures for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $63.4 million.
- RedHill Biopharma's Gains from Sales and Divestitures rose 82.27% to $63.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $63.4 million, marking a year-over-year increase of 82.27%. This contributed to the annual value of $35.0 million for FY2024, which is 63.41% up from last year.
- As of Q2 2025, RedHill Biopharma's Gains from Sales and Divestitures stood at $63.4 million, which was up 80.97% from $35.0 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Gains from Sales and Divestitures registered a high of $63.4 million during Q2 2025, and its lowest value of $1.3 million during Q1 2021.
- Over the past 3 years, RedHill Biopharma's median Gains from Sales and Divestitures value was $28.1 million (recorded in 2023), while the average stood at $27.0 million.
- Data for RedHill Biopharma's Gains from Sales and Divestitures shows a peak YoY skyrocketed of 656.30% (in 2023) over the last 5 years.
- RedHill Biopharma's Gains from Sales and Divestitures (Quarterly) stood at $1.5 million in 2021, then soared by 89.63% to $2.8 million in 2022, then surged by 656.30% to $21.4 million in 2023, then skyrocketed by 63.41% to $35.0 million in 2024, then soared by 82.27% to $63.4 million in 2025.
- Its Gains from Sales and Divestitures was $63.4 million in Q2 2025, compared to $35.0 million in Q4 2024 and $34.8 million in Q2 2024.